Non-Cell Lung Cancer Therapeutics Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2029
13.4%
CAGR (2023-2029)
22.92 USD Bn.
Market Size
304
Report Pages
124
Market Tables
Overview
Non-Small Cell Lung Cancer Therapeutics Market is expected to reach US$ 55.29 Bn. at a CAGR of 13.4 during the forecast period 2029.
The demand for targeted therapy for the diagnosis will increase, growing penetration of drugs, hereditary causes of cancer and several factors that cause lung cancer include pollution and smoking are driving in global non-small cell lung cancer therapeutics market. Moreover, the ongoing research and development of non-small cell lung cancer therapies, growing focus on healthcare sectors, and the introduction of new drugs are estimated to further opportunities in this market. 
To know about the Research Methodology :- Request Free Sample Report
By therapy the immunotherapy segment expected to dominate the xx% market share during the forecast period. The immunotherapy segment is cancer treatment which boosts the natural immune system of the human body in fighting against the cancer cells. Alcoholism and smoking have increased tremendously, which is highly responsible for cancer. Immunotherapy is high in demand because of the increasing cancer population across the globe.
The hospital Pharmacies segment is to dominate the xx% market share during the forecast period. The increasing number of hospital admittance because of the growing prevalence of adenocarcinoma and squamous cell carcinoma. The hospital pharmacies segment preserve the standard of products related to cervical cancer for out-patients, as well as for in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing in the market.
North America is expected to account for the largest share of the non-small cell lung cancer therapeutics market during the forecast period. The government of North America supports the research activity that effects the up-gradation of existing drugs and the development of new advanced and effective drugs is increasing. Establishment of major performers and advancements in these sectors are expected to improve in the market of non-small cell lung cancer therapeutics in this region.
The objective of the report is to present a comprehensive analysis of Global Non-Small Cell Lung Cancer Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Non-Small Cell Lung Cancer Therapeutics Market dynamics, structure by analysing the market segments and project the Global Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product Portfolio, Growth strategies, and Regional presence in the Global Non-Small Cell Lung Cancer Therapeutics Market make the report investor’s guide.
The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Scope of the Global Non-Small Cell Lung Cancer Therapeutics Market: Inquire before buying
| Global Non-Cell Lung Cancer Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 22.92 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 13.4% | Market Size in 2029: | US $ 55.29 Bn. |
| Segments Covered: | by Therapy | Targeted Therapy Bevacizumab Dabrafenib/Trametinib Erlotinib Hydrochloride Osimertinib Others Immunotherapy Durvalumab Nivolumab Atezolizumab Pembrolizumab Chemotherapy |
|
| by Distribution Channel | Hospital Pharmacies Retail Pharmacies Online Pharmacies |
||
| by Cancer | Adenocarcinoma Squamous cell carcinoma Large cell carcinoma |
||
Non-Small Cell Lung Cancer Therapeutics Market, By Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key players operating in the Global Non-Small Cell Lung Cancer Therapeutics Market
1. Astrazeneca PLC
2. Eli Lilly and company
3. Sanofi-Aventis
4. Arqule Inc
5. Daiichi Sankyo co. Ltd
6. Pfizer Inc
7. Bristol-Myers Squibb Company
8. Orion Corporation
9. Merck KGaA
10.AstraZeneca
11.F. Hoffmann-La Roche Ltd
12.GlaxoSmithKline Plc
13.Novartis AG
14.Celgene Corporation
15.Boehringer Ingeheim Pharmaceuticals, Inc.
16.Millennium Pharmaceuticals, Inc.
17.Merck Sharp & Dohme Corp
Frequently Asked Questions:
1. Which region has the largest share in Global Non-Cell Lung Cancer Therapeutics Market?
Ans: North America region holds the highest share in 2022.
2. What is the growth rate of Global Non-Small Cell Lung Cancer Market?
Ans: The Global Therapeutics Market is growing at a CAGR of 13.4% during forecasting period 2023-2029.
3. What is scope of the Global Market report?
Ans: Global Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. What is the study period of this market?
Ans: The Global Therapeutics Market is studied from 2022 to 2029.
Table of Contents
Global Non-Small Cell Lung Cancer Therapeutics Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Non-Small Cell Lung Cancer Therapeutics Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast
6.1. Global Non-Small Cell Lung Cancer Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Drug Class
7.4. Global Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Bn) Forecast, by Drug Class
7.5. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Drug Class
7.6. Global Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis, by Drug Class
8. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast, by Disease Indication
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Disease Indication
8.4. Global Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication
8.5. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Disease Indication
8.6. Global Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis, by Disease Indication
9. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
9.4. Global Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel
9.5. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Distribution Channel
9.6. Global Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel
10. Global Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Region
10.1. Global Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Region
10.2. Global Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Bn) Forecast, by Region
10.3. Global Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis, by Region
11. North America Non-Small Cell Lung Cancer Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Non-Small Cell Lung Cancer Therapeutics Market Overview
11.3. North America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Drug Class
11.4. North America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
11.4.1. TNF (Tumor Necrosis Factor)Inhibitors
11.4.2. Aminosalicyclates
11.4.3. Immunomodulators
11.4.4. Corticosteroids
11.4.5. Biologics
11.4.6. Antibiotics
11.5. North America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Disease Indication
11.6. North America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
11.6.1. Ulcerative Colitis
11.6.2. Crohn’s Disease
11.7. North America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
11.8. North America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. North America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Country
11.10. North America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Country
11.12. U.S. Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
11.12.1. TNF (Tumor Necrosis Factor)Inhibitors
11.12.2. Aminosalicyclates
11.12.3. Immunomodulators
11.12.4. Corticosteroids
11.12.5. Biologics
11.12.6. Antibiotics
11.13. U.S. Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
11.13.1. Ulcerative Colitis
11.13.2. Crohn’s Disease
11.14. U.S. Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
11.14.1. Hospital Pharmacies
11.14.2. Retail Pharmacies
11.14.3. Online Pharmacies
11.15. Canada Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
11.15.1. TNF (Tumor Necrosis Factor)Inhibitors
11.15.2. Aminosalicyclates
11.15.3. Immunomodulators
11.15.4. Corticosteroids
11.15.5. Biologics
11.15.6. Antibiotics
11.16. Canada Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
11.16.1. Ulcerative Colitis
11.16.2. Crohn’s Disease
11.17. Canada Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Retail Pharmacies
11.17.3. Online Pharmacies
11.18. North America Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis
11.18.1. By Drug Class
11.18.2. By Disease Indication
11.18.3. By Distribution Channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Non-Small Cell Lung Cancer Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Non-Small Cell Lung Cancer Therapeutics Market Overview
12.3. Europe Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Drug Class
12.4. Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.4.1. TNF (Tumor Necrosis Factor)Inhibitors
12.4.2. Aminosalicyclates
12.4.3. Immunomodulators
12.4.4. Corticosteroids
12.4.5. Biologics
12.4.6. Antibiotics
12.5. Europe Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Disease Indication
12.6. Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.6.1. Ulcerative Colitis
12.6.2. Crohn’s Disease
12.7. Europe Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
12.8. Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Europe Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Country
12.10. Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Country
12.12. Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.12.1. TNF (Tumor Necrosis Factor)Inhibitors
12.12.2. Aminosalicyclates
12.12.3. Immunomodulators
12.12.4. Corticosteroids
12.12.5. Biologics
12.12.6. Antibiotics
12.13. Germany Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.13.1. Ulcerative Colitis
12.13.2. Crohn’s Disease
12.14. Germany Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.14.1. Hospital Pharmacies
12.14.2. Retail Pharmacies
12.14.3. Online Pharmacies
12.15. U.K. Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.15.1. TNF (Tumor Necrosis Factor)Inhibitors
12.15.2. Aminosalicyclates
12.15.3. Immunomodulators
12.15.4. Corticosteroids
12.15.5. Biologics
12.15.6. Antibiotics
12.16. U.K. Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.16.1. Ulcerative Colitis
12.16.2. Crohn’s Disease
12.17. U.K. Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Retail Pharmacies
12.17.3. Online Pharmacies
12.18. France Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.18.1. TNF (Tumor Necrosis Factor)Inhibitors
12.18.2. Aminosalicyclates
12.18.3. Immunomodulators
12.18.4. Corticosteroids
12.18.5. Biologics
12.18.6. Antibiotics
12.19. France Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.19.1. Ulcerative Colitis
12.19.2. Crohn’s Disease
12.20. France Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.20.1. Hospital Pharmacies
12.20.2. Retail Pharmacies
12.20.3. Online Pharmacies
12.21. Italy Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.21.1. TNF (Tumor Necrosis Factor)Inhibitors
12.21.2. Aminosalicyclates
12.21.3. Immunomodulators
12.21.4. Corticosteroids
12.21.5. Biologics
12.21.6. Antibiotics
12.22. Italy Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.22.1. Ulcerative Colitis
12.22.2. Crohn’s Disease
12.23. Italy Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.23.1. Hospital Pharmacies
12.23.2. Retail Pharmacies
12.23.3. Online Pharmacies
12.24. Spain Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.24.1. TNF (Tumor Necrosis Factor)Inhibitors
12.24.2. Aminosalicyclates
12.24.3. Immunomodulators
12.24.4. Corticosteroids
12.24.5. Biologics
12.24.6. Antibiotics
12.25. Spain Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.25.1. Ulcerative Colitis
12.25.2. Crohn’s Disease
12.26. Spain Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.26.1. Hospital Pharmacies
12.26.2. Retail Pharmacies
12.26.3. Online Pharmacies
12.27. Rest of Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
12.27.1. TNF (Tumor Necrosis Factor)Inhibitors
12.27.2. Aminosalicyclates
12.27.3. Immunomodulators
12.27.4. Corticosteroids
12.27.5. Biologics
12.27.6. Antibiotics
12.28. Rest of Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
12.28.1. Ulcerative Colitis
12.28.2. Crohn’s Disease
12.29. Rest Of Europe Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
12.29.1. Hospital Pharmacies
12.29.2. Retail Pharmacies
12.29.3. Online Pharmacies
12.30. Europe Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis
12.30.1. By Drug Class
12.30.2. By Disease Indication
12.30.3. By Distribution Channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Overview
13.3. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Drug Class
13.4. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
13.4.1. TNF (Tumor Necrosis Factor)Inhibitors
13.4.2. Aminosalicyclates
13.4.3. Immunomodulators
13.4.4. Corticosteroids
13.4.5. Biologics
13.4.6. Antibiotics
13.5. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, By Disease Indication
13.6. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
13.6.1. Ulcerative Colitis
13.6.2. Crohn’s Disease
13.7. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
13.8. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Country
13.12. China Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
13.12.1. TNF (Tumor Necrosis Factor)Inhibitors
13.12.2. Aminosalicyclates
13.12.3. Immunomodulators
13.12.4. Corticosteroids
13.12.5. Biologics
13.12.6. Antibiotics
13.13. China Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
13.13.1. Ulcerative Colitis
13.13.2. Crohn’s Disease
13.14. China Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
13.14.1. Hospital Pharmacies
13.14.2. Retail Pharmacies
13.14.3. Online Pharmacies
13.15. India Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
13.15.1. TNF (Tumor Necrosis Factor)Inhibitors
13.15.2. Aminosalicyclates
13.15.3. Immunomodulators
13.15.4. Corticosteroids
13.15.5. Biologics
13.15.6. Antibiotics
13.16. India Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
13.16.1. Ulcerative Colitis
13.16.2. Crohn’s Disease
13.17. India Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
13.17.1. Hospital Pharmacies
13.17.2. Retail Pharmacies
13.17.3. Online Pharmacies
13.18. Japan Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
13.18.1. TNF (Tumor Necrosis Factor)Inhibitors
13.18.2. Aminosalicyclates
13.18.3. Immunomodulators
13.18.4. Corticosteroids
13.18.5. Biologics
13.18.6. Antibiotics
13.19. Japan Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
13.19.1. Ulcerative Colitis
13.19.2. Crohn’s Disease
13.20. Japan Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
13.20.1. Hospital Pharmacies
13.20.2. Retail Pharmacies
13.20.3. Online Pharmacies
13.21. ASEAN Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
13.21.1. TNF (Tumor Necrosis Factor)Inhibitors
13.21.2. Aminosalicyclates
13.21.3. Immunomodulators
13.21.4. Corticosteroids
13.21.5. Biologics
13.21.6. Antibiotics
13.22. ASEAN Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
13.22.1. Ulcerative Colitis
13.22.2. Crohn’s Disease
13.23. ASEAN Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
13.23.1. Hospital Pharmacies
13.23.2. Retail Pharmacies
13.23.3. Online Pharmacies
13.24. Rest of Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
13.24.1. TNF (Tumor Necrosis Factor)Inhibitors
13.24.2. Aminosalicyclates
13.24.3. Immunomodulators
13.24.4. Corticosteroids
13.24.5. Biologics
13.24.6. Antibiotics
13.25. Rest of Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
13.25.1. Ulcerative Colitis
13.25.2. Crohn’s Disease
13.26. Rest of Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
13.26.1. Hospital Pharmacies
13.26.2. Retail Pharmacies
13.26.3. Online Pharmacies
13.27. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis
13.27.1. By Drug Class
13.27.2. By Disease Indication
13.27.3. By Distribution Channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Overview
14.3. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Drug Class
14.4. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
14.4.1. TNF (Tumor Necrosis Factor)Inhibitors
14.4.2. Aminosalicyclates
14.4.3. Immunomodulators
14.4.4. Corticosteroids
14.4.5. Biologics
14.4.6. Antibiotics
14.5. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, By Disease Indication
14.6. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
14.6.1. Ulcerative Colitis
14.6.2. Crohn’s Disease
14.7. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
14.8. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Country
14.12. GCC Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
14.12.1. TNF (Tumor Necrosis Factor)Inhibitors
14.12.2. Aminosalicyclates
14.12.3. Immunomodulators
14.12.4. Corticosteroids
14.12.5. Biologics
14.12.6. Antibiotics
14.13. GCC Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
14.13.1. Ulcerative Colitis
14.13.2. Crohn’s Disease
14.14. GCC Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
14.14.1. Hospital Pharmacies
14.14.2. Retail Pharmacies
14.14.3. Online Pharmacies
14.15. South Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
14.15.1. TNF (Tumor Necrosis Factor)Inhibitors
14.15.2. Aminosalicyclates
14.15.3. Immunomodulators
14.15.4. Corticosteroids
14.15.5. Biologics
14.15.6. Antibiotics
14.16. South Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
14.16.1. Ulcerative Colitis
14.16.2. Crohn’s Disease
14.17. South Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
14.17.1. Hospital Pharmacies
14.17.2. Retail Pharmacies
14.17.3. Online Pharmacies
14.18. Rest of Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
14.18.1. TNF (Tumor Necrosis Factor)Inhibitors
14.18.2. Aminosalicyclates
14.18.3. Immunomodulators
14.18.4. Corticosteroids
14.18.5. Biologics
14.18.6. Antibiotics
14.19. Rest of Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
14.19.1. Ulcerative Colitis
14.19.2. Crohn’s Disease
14.20. Rest of Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
14.20.1. Hospital Pharmacies
14.20.2. Retail Pharmacies
14.20.3. Online Pharmacies
14.21. Middle East & Africa Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis
14.21.1.1. By Drug Class
14.21.1.2. By Disease Indication
14.21.1.3. By Distribution Channel
14.21.1.4. PEST Analysis
14.21.1.5. Key Trends
14.21.1.6. Key Developments
15. South America Non-Small Cell Lung Cancer Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Non-Small Cell Lung Cancer Therapeutics Market Overview
15.3. South America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Drug Class
15.4. South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
15.4.1. TNF (Tumor Necrosis Factor)Inhibitors
15.4.2. Aminosalicyclates
15.4.3. Immunomodulators
15.4.4. Corticosteroids
15.4.5. Biologics
15.4.6. Antibiotics
15.5. South America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, By Disease Indication
15.6. South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
15.6.1. Ulcerative Colitis
15.6.2. Crohn’s Disease
15.7. South America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
15.8. South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. South America Non-Small Cell Lung Cancer Therapeutics Market Value Share Analysis, by Country
15.10. South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Non-Small Cell Lung Cancer Therapeutics Market Analysis, by Country
15.12. Brazil Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
15.12.1. TNF (Tumor Necrosis Factor)Inhibitors
15.12.2. Aminosalicyclates
15.12.3. Immunomodulators
15.12.4. Corticosteroids
15.12.5. Biologics
15.12.6. Antibiotics
15.13. Brazil Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
15.13.1. Ulcerative Colitis
15.13.2. Crohn’s Disease
15.14. Brazil Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
15.14.1. Hospital Pharmacies
15.14.2. Retail Pharmacies
15.14.3. Online Pharmacies
15.15. Mexico Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
15.15.1. TNF (Tumor Necrosis Factor)Inhibitors
15.15.2. Aminosalicyclates
15.15.3. Immunomodulators
15.15.4. Corticosteroids
15.15.5. Biologics
15.15.6. Antibiotics
15.16. Mexico Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
15.16.1. Ulcerative Colitis
15.16.2. Crohn’s Disease
15.17. Mexico Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
15.17.1. Hospital Pharmacies
15.17.2. Retail Pharmacies
15.17.3. Online Pharmacies
15.17.3.1. Contract Manufacturing Organizations
15.18. Rest of South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Drug Class
15.18.1. TNF (Tumor Necrosis Factor)Inhibitors
15.18.2. Aminosalicyclates
15.18.3. Immunomodulators
15.18.4. Corticosteroids
15.18.5. Biologics
15.18.6. Antibiotics
15.19. Rest of South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Disease Indication
15.19.1. Ulcerative Colitis
15.19.2. Crohn’s Disease
15.20. Rest of South America Non-Small Cell Lung Cancer Therapeutics Market Forecast, by Distribution Channel
15.20.1. Hospital Pharmacies
15.20.2. Retail Pharmacies
15.20.3. Online Pharmacies
15.21. South America Non-Small Cell Lung Cancer Therapeutics Market Attractiveness Analysis
15.21.1. By Drug Class
15.21.2. By Disease Indication
15.21.3. By Distribution Channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Valeant Pharmaceuticals International
16.3.3. Novartis AG
16.3.4. Janssen Biotech Inc.
16.3.5. Alkem Laboratories Limited
16.3.6. AbbVie Inc.
16.3.7. UCB Inc
16.3.8. Takeda Pharmaceutical Company Limited
16.3.9. Biogen Inc.
16.3.10. Pfizer Inc.
16.3.11. Allergan plc
16.3.12. Celltrion Healthcare
16.3.13. Innovate Biopharmaceuticals
16.3.14. Gilead Sciences
16.3.15. Celgene Corporation
16.3.16. Boehringer Ingeheim Pharmaceuticals, Inc.
16.3.17. Millennium Pharmaceuticals, Inc.
16.3.18. Merck Sharp & Dohme Corp
17. Primary Key Insights